Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma

Tae Hyung Kim, Sangjoon Park, Chai Hong Rim, Chiwhan Choi, Jinsil Seong

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: For bone metastasis from hepatocellular carcinoma (HCC), radiotherapy (RT) has been used a palliative treatment with little impact on survival. Currently, ablative RT is popularly used, and a more than palliative effect is expected. Herein, we investigated the clinical efficacy of ablative RT in patients with bone metastasis from HCC. Methods: In total, 530 patients with 887 lesions treated in 1992–2019 were reviewed. Oligometastasis was defined as the presence of < 5 lesions. Total doses were normalized to obtain biologically effective doses (BEDs). The cut-off threshold of the BED was determined via receiver operating characteristics curve analysis. The Kaplan–Meier method was used to calculate overall survival (OS); propensity score matching (PSM) was performed to balance the heterogeneity in cases while comparing BEDs of ≥ 60 and < 60 Gy. Results: The most common site of metastasis was the spine (59%); 59 patients (11%) presented with oligometastasis, and 76.2% of patients showed objective pain palliation after RT. Median OS was 5.1 months for all patients; patients with oligometastasis showed longer OS than those without (9.8 vs. 4.7 months). A Cox proportional hazards model showed that performance status, Child–Pugh class, extraosseous metastasis, primary HCC status, α-fetoprotein level, and radiation dose (BED) were significant prognostic factors. Post PSM, BED was the only treatment-related prognostic factor that remained significant; the median OS durations were 8.1 and 4.4 months when the BEDs were ≥ 60 and < 60 Gy, respectively. Conclusion: Ablative RT improved OS and pain palliation in patients with bone metastasis from HCC.

Original languageEnglish
JournalJournal of cancer research and clinical oncology
DOIs
Publication statusAccepted/In press - 2021

Bibliographical note

Funding Information:
This study was supported by the Dong-A research fund (Grant Number: 2018-31-0904).

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this